Assessment of Fetal Rhesus D and Gender with Cell-Free DNA and Exosomes from Maternal Blood

Yaşa, Büşra; Şahin, Orhan; Öcüt, Elif; Seven, Mehmet; Sözer, Selçuk

doi:10.1007/s43032-020-00321-4

Cited by 12 publications

(14 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Following with the improved performance of EV-DNA tests, in a recent study, the assessment of Rhesus D genotype and gender by coupling quantitative PCR to EV-DNA and cfDNA isolation from maternal blood gave successful results with both approaches although only EV-DNA achieved a 100% of sensitivity and specificity for both assays (Yaşa et al, 2020).…”

Section: Cfdna Vs Ev-na Who Is the Winner?mentioning

confidence: 99%

DNA-Loaded Extracellular Vesicles in Liquid Biopsy: Tiny Players With Big Potential?

García‐Silva

Gallardo

Peinado

2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Section: Cfdna Vs Ev-na Who Is the Winner?mentioning

confidence: 99%

DNA-Loaded Extracellular Vesicles in Liquid Biopsy: Tiny Players With Big Potential?

García‐Silva

Gallardo

Peinado

2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

“…Yakın zamanda yaptığımız bir çalışmada invaziv olmayan yöntem ile maternal kandan elde edilen hdfDNA ve hatta eksozom ile gerçek-zamanlı PZR yöntemi kullanarak fetal RHD ve SRY genotiplemesinin başarılı olduğu gösterildi. Bu yöntemin her hasta için uygulanabilir ve güvenilir olduğu tarafımızdan tespit edildi (11). Ülkemizde, prenatal tanıda kullanılan yöntemler sırasında karşılaşılan tanı zorluğu ve bu kaotik süreçte hastaya yansıyan maddi ve manevi zorluklar dikkati çekmektedir.…”

Section: öZunclassified

“…Maliyetler farklı stratejilerle azaltılabilse de, elde ettiğimiz sonuç bu ve benzeri güncel tanı yaklaşımlarının etkin bir maliyet düşürme stratejisi olduğunu göstermektedir. Yapmış olduğumuz önceki çalışmada, Türkiye'de RhD (-) gebeden doğan RhD (-) bebek oranının %10 olduğu tespit edildi (11). Bu gebelerin gereksiz anti-D gibi kan ürünü almalarının önüne geçilmesi ve yanlış kullanımın önüne geçilmesini sağlayacaktır.…”

Section: öZunclassified

“…Yalancı pozitiflik durumunda yapılacak olan tüm bu işlemler anne ve fetüs için yıpratıcı olmaktadır. İnvaziv olmayan yöntem ile maternal kandan elde edilen hdfDNA ile gerçek-zamanlı PZR yöntemi kullanarak fetal RHD genotipleme başarısı tarafımızdan ve farklı gruplar tarafından tespit edilmiştir (11,(13)(14)(15) Maliyet avantajı açısından öne çıkan gerçek zamanlı PZR yöntemi aynı zamandan uygulanabilirlik olarak da en kolay ve ucuz yöntemlerden bir tanesidir. Son dönemlerde daha hassas olması bakımından tanı alanında kendine hızlı yer edinen yeni nesil dizileme tekniğine göre pratikliği, sarf malzeme alanında ki çeşitliliği, teknik eleman yeterliliği ve uygulanabilirliği yönüyle kısa sürede etkinliğini gösterecektir.…”

Section: Sonuçlar Ve Tartişmaunclassified

“…Uygulanılan bu yöntem, yaklaşık 3,5 kat daha az bir maliyet ile RhD uyuşmazlığının tanıdaki başarısını arttırmakta ve gereksiz proflaksi uygulanmasının önüne geçilebilmektedir. (11).…”

Section: Introductionunclassified

See 2 more Smart Citations

Hücre-dışı Fetal DNA‘dan Gerçek-zamanlı PZR ile Fetal Rhesus D Tespitinin Maliyet Değerlendirmesi

Yaşa¹,

Şahin²,

Tokdemir³

2020

Experimed

Self Cite

View full text Add to dashboard Cite

The detection of cell-free fetal DNA (cffDNA) from maternal plasma has enabled the development of essential prenatal diagnostic techniques supporting the non-invasive screening and diagnostic tests in recent years.We performed a non-invasive real-time polymerase chain reaction (PCR) using cell-free DNA isolated from the peripheral blood of pregnant women to determine fetal Rhesus D (RhD) and sex. Consistent with the findings of similar studies, our results revealed high accuracy rates of PCR in determining fetal RhD, making it suitable for diagnostic use, thereby indicating its effectiveness as a guide in treating and especially in minimizing the procedures applied to pregnant women who are RhD negative.This study compared the cost incurred between follow-up testing and treatment of RhD (-) pregnant women and the fetal RHD genotyping based on Health Implementation Notification (SUT) data of the Social Security Administration of the Republic of Turkey. Additionally, the role of PCR to the diagnostic process was evaluated.Our results showed that fetal RHD genotyping costs 523.19 TL (3.5 times) less for each RhD (-) pregnant women compared with the current additional tests and treatments. PCR with cffDNA is an innovative method that minimizes workload, hospital costs, and unnecessary tests and treatment. In addition, this method allows an early initiation of treatment and avoidance of unnecessary intervention and cost.

show abstract

EV‐ADD, a database for EV‐associated DNA in human liquid biopsy samples

Tsering

Chen

et al. 2022

J of Extracellular Vesicle

View full text Add to dashboard Cite

Extracellular vesicles (EVs) play a key role in cellular communication both in physiological conditions and in pathologies such as cancer. Emerging evidence has shown that EVs are active carriers of molecular cargo (e.g. protein and nucleic acids) and a powerful source of biomarkers and targets. While recent studies on EV‐associated DNA (EV‐DNA) in human biofluids have generated a large amount of data, there is currently no database that catalogues information on EV‐DNA. To fill this gap, we have manually curated a database of EV‐DNA data derived from human biofluids (liquid biopsy) and in‐vitro studies, called the Extracellular Vesicle‐Associated DNA Database (EV‐ADD). This database contains validated experimental details and data extracted from peer‐reviewed published literature. It can be easily queried to search for EV isolation methods and characterization, EV‐DNA isolation techniques, quality validation, DNA fragment size, volume of starting material, gene names and disease context. Currently, our database contains samples representing 23 diseases, with 13 different types of EV isolation techniques applied on eight different human biofluids (e.g. blood, saliva). In addition, EV‐ADD encompasses EV‐DNA data both representing the whole genome and specifically including oncogenes, such as KRAS, EGFR, BRAF, MYC, and mitochondrial DNA (mtDNA). An EV‐ADD data metric system was also integrated to assign a compliancy score to the MISEV guidelines based on experimental parameters reported in each study. While currently available databases document the presence of proteins, lipids, RNA and metabolites in EVs (e.g. Vesiclepedia, ExoCarta, ExoBCD, EVpedia, and EV‐TRACK), to the best of our knowledge, EV‐ADD is the first of its kind to compile all available EV‐DNA datasets derived from human biofluid samples. We believe that this database provides an important reference resource on EV‐DNA‐based liquid biopsy research, serving as a learning tool and to showcase the latest developments in the EV‐DNA field. EV‐ADD will be updated yearly as newly published EV‐DNA data becomes available and it is freely available at http://www.evdnadatabase.com.

show abstract

Assessment of Fetal Rhesus D and Gender with Cell-Free DNA and Exosomes from Maternal Blood

Cited by 12 publications

References 40 publications

DNA-Loaded Extracellular Vesicles in Liquid Biopsy: Tiny Players With Big Potential?

DNA-Loaded Extracellular Vesicles in Liquid Biopsy: Tiny Players With Big Potential?

Hücre-dışı Fetal DNA‘dan Gerçek-zamanlı PZR ile Fetal Rhesus D Tespitinin Maliyet Değerlendirmesi

EV‐ADD, a database for EV‐associated DNA in human liquid biopsy samples

Contact Info

Product

Resources

About